Related references
Note: Only part of the references are listed.Therapeutic Potential of HSP90 Inhibition for Neurofibromatosis Type 2
Karo Tanaka et al.
CLINICAL CANCER RESEARCH (2013)
mTORC1 Inhibitors Suppress Meningioma Growth in Mouse Models
Doreen Pachow et al.
CLINICAL CANCER RESEARCH (2013)
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
David Neal Franz et al.
LANCET (2013)
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer
Andrea Lunardi et al.
NATURE GENETICS (2013)
Conservative Management of Bilateral Vestibular Schwannomas in Neurofibromatosis Type 2 Patients: Hearing and Tumor Growth Results
Matthieu Peyre et al.
NEUROSURGERY (2013)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus
Wei Li et al.
EMBO REPORTS (2012)
Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors Clinical article
Michael S. Dirks et al.
JOURNAL OF NEUROSURGERY (2012)
Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2-Deficient Target Cell Types
Marianne F. James et al.
MOLECULAR CANCER RESEARCH (2012)
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Zhao Chen et al.
NATURE (2012)
Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features
Stphane Goutagny et al.
NEURO-ONCOLOGY (2012)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 20052009
Therese A. Dolecek et al.
NEURO-ONCOLOGY (2012)
mTOR as a potential treatment target for epilepsy
Michael Wong
FUTURE NEUROLOGY (2012)
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2
Jaishri O. Blakeley et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2011)
Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis
David Neal Franz
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
The APL Paradigm and the Co-Clinical Trial Project
Caterina Nardella et al.
CANCER DISCOVERY (2011)
Birth Incidence and Prevalence of Tumor-Prone Syndromes: Estimates From a UK Family Genetic Register Service
D. G. Evans et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2010)
Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition
Calvin K. Yip et al.
MOLECULAR CELL (2010)
Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2
Victor-Felix Mautner et al.
NEURO-ONCOLOGY (2010)
Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas
K. D. Hadfield et al.
ONCOGENE (2010)
Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2
D. Gareth Evans et al.
CLINICAL CANCER RESEARCH (2009)
Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling
Miguel A. Lopez-Lago et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth
Marianne F. James et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
Scott R. Plotkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Merlin and the ERM proteins - regulators of receptor distribution and signaling at the cell cortex
Andrea I. McClatchey et al.
TRENDS IN CELL BIOLOGY (2009)
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Nancy Lee et al.
BMC Pharmacology & Toxicology (2009)
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
Haesun Choi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
Thuy L. Phung et al.
CANCER CELL (2006)
User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability
Paul A. Yushkevich et al.
NEUROIMAGE (2006)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Cancer-specific mutations in PIK3CA are oncogenic in vivo
AG Bader et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways
DJ Kwiatkowski et al.
HUMAN MOLECULAR GENETICS (2005)
Membrane organization and tumorigenesis - the NF2 tumor suppressor, Merlin
AI McClatchey et al.
GENES & DEVELOPMENT (2005)
Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas
C Mawrin et al.
CLINICAL CANCER RESEARCH (2005)
Comparative pathology of nerve sheath tumors in mouse models and humans
AO Stemmer-Rachamimov et al.
CANCER RESEARCH (2004)
MTOR interacts with Raptor to form a nutrient-sensitive complex that signals to the cell growth machinery
DH Kim et al.
CELL (2002)
Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E
DC Fingar et al.
GENES & DEVELOPMENT (2002)
The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human schwannoma cells
AM Bashour et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Share Paper
